Update on the Diagnosis and Prognosis of Preeclampsia with the Aid of the sFlt-1/ PlGF Ratio in Singleton Pregnancies

Preeclampsia (PE) is involved in a group of obstetrical conditions closely related by the presence of placental dysfunction (PD), which also includes intrauterine growth restriction and placental abruption. The timely and accurate recognition and management of PE are often challenging because diagno...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Fetal diagnosis and therapy 2018-01, Vol.43 (2), p.81-89
Hauptverfasser: Herraiz, Ignacio, Llurba, Elisa, Verlohren, Stefan, Galindo, Alberto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 89
container_issue 2
container_start_page 81
container_title Fetal diagnosis and therapy
container_volume 43
creator Herraiz, Ignacio
Llurba, Elisa
Verlohren, Stefan
Galindo, Alberto
description Preeclampsia (PE) is involved in a group of obstetrical conditions closely related by the presence of placental dysfunction (PD), which also includes intrauterine growth restriction and placental abruption. The timely and accurate recognition and management of PE are often challenging because diagnostic criteria are still based on nonspecific signs and symptoms and because common severity criteria correlate poorly with adverse maternal and fetal outcomes. The discovery of the role of angiogenesis-related factors - soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) - in the underlying pathophysiology of PD has marked an important step for improving its early diagnosis and prognosis assessment before gestational week 34. Nowadays, an sFlt-1/PlGF ratio cutoff level of ≤38 is widely accepted for ruling out PE in patients with suspicion of the disease, and its use is cost-effective. However, the evidence is more limited regarding the management and prognosis of women with an abnormally high sFlt-1/PlGF ratio. This review summarizes the current evidence of the clinical application of the sFlt-1/PlGF ratio for the diagnosis and prognosis assessment of PE and points out the next challenges for these biomarkers, including their role as target for the development and monitoring of new therapies.
doi_str_mv 10.1159/000477903
format Article
fullrecord <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_477903</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1920391744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c341t-cc3942dfa3fc0e13acfc3f2ffde8cb6b50363aa2d3812b949101ff54666c9af23</originalsourceid><addsrcrecordid>eNo9kEtPwzAQhC0EouVx4I6Qj3AI9StOfKwKLUiVqICeI8exU0MexU6E-Pe4NPS0s9pvRtoB4Aqje4xjMUEIsSQRiB6BMWYER0Jwdhw0wnFEU5qMwJn3HwFLE8pPwYikCRap4GPQr7eF7DRsG9htNHywsmxabz2UTQFXrh221oRFa1XJeuuthN-22_wZprbYHXfSz6suwhO4qhZz-Co720LbwDfblJXuQn4IKBvZKKv9BTgxsvL6cpjnYD1_fJ89RcuXxfNsuowUZbiLlKKCkcJIahTSmEplFDXEmEKnKud5jCinUpKCppjkgonwsDEx45wrIQ2h5-B2n7t17VevfZfV1itdVbLRbe8zLAiiAieMBfRujyrXeu-0ybbO1tL9ZBhlu5azQ8uBvRli-7zWxYH8rzUA13vgU7pSuwMw-H8BvXCAMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1920391744</pqid></control><display><type>article</type><title>Update on the Diagnosis and Prognosis of Preeclampsia with the Aid of the sFlt-1/ PlGF Ratio in Singleton Pregnancies</title><source>Karger Journal Archive Collection</source><source>Karger Journals Complete</source><source>Alma/SFX Local Collection</source><creator>Herraiz, Ignacio ; Llurba, Elisa ; Verlohren, Stefan ; Galindo, Alberto</creator><creatorcontrib>Herraiz, Ignacio ; Llurba, Elisa ; Verlohren, Stefan ; Galindo, Alberto ; Spanish Group for the Study of Angiogenic Markers in Preeclampsia ; on behalf of the Spanish Group for the Study of Angiogenic Markers in Preeclampsia</creatorcontrib><description>Preeclampsia (PE) is involved in a group of obstetrical conditions closely related by the presence of placental dysfunction (PD), which also includes intrauterine growth restriction and placental abruption. The timely and accurate recognition and management of PE are often challenging because diagnostic criteria are still based on nonspecific signs and symptoms and because common severity criteria correlate poorly with adverse maternal and fetal outcomes. The discovery of the role of angiogenesis-related factors - soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) - in the underlying pathophysiology of PD has marked an important step for improving its early diagnosis and prognosis assessment before gestational week 34. Nowadays, an sFlt-1/PlGF ratio cutoff level of ≤38 is widely accepted for ruling out PE in patients with suspicion of the disease, and its use is cost-effective. However, the evidence is more limited regarding the management and prognosis of women with an abnormally high sFlt-1/PlGF ratio. This review summarizes the current evidence of the clinical application of the sFlt-1/PlGF ratio for the diagnosis and prognosis assessment of PE and points out the next challenges for these biomarkers, including their role as target for the development and monitoring of new therapies.</description><identifier>ISSN: 1015-3837</identifier><identifier>EISSN: 1421-9964</identifier><identifier>DOI: 10.1159/000477903</identifier><identifier>PMID: 28719896</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Mini-Review</subject><ispartof>Fetal diagnosis and therapy, 2018-01, Vol.43 (2), p.81-89</ispartof><rights>2017 S. Karger AG, Basel</rights><rights>2017 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c341t-cc3942dfa3fc0e13acfc3f2ffde8cb6b50363aa2d3812b949101ff54666c9af23</citedby><orcidid>0000-0003-4048-6407 ; 0000-0003-3507-8636</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28719896$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Herraiz, Ignacio</creatorcontrib><creatorcontrib>Llurba, Elisa</creatorcontrib><creatorcontrib>Verlohren, Stefan</creatorcontrib><creatorcontrib>Galindo, Alberto</creatorcontrib><creatorcontrib>Spanish Group for the Study of Angiogenic Markers in Preeclampsia</creatorcontrib><creatorcontrib>on behalf of the Spanish Group for the Study of Angiogenic Markers in Preeclampsia</creatorcontrib><title>Update on the Diagnosis and Prognosis of Preeclampsia with the Aid of the sFlt-1/ PlGF Ratio in Singleton Pregnancies</title><title>Fetal diagnosis and therapy</title><addtitle>Fetal Diagn Ther</addtitle><description>Preeclampsia (PE) is involved in a group of obstetrical conditions closely related by the presence of placental dysfunction (PD), which also includes intrauterine growth restriction and placental abruption. The timely and accurate recognition and management of PE are often challenging because diagnostic criteria are still based on nonspecific signs and symptoms and because common severity criteria correlate poorly with adverse maternal and fetal outcomes. The discovery of the role of angiogenesis-related factors - soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) - in the underlying pathophysiology of PD has marked an important step for improving its early diagnosis and prognosis assessment before gestational week 34. Nowadays, an sFlt-1/PlGF ratio cutoff level of ≤38 is widely accepted for ruling out PE in patients with suspicion of the disease, and its use is cost-effective. However, the evidence is more limited regarding the management and prognosis of women with an abnormally high sFlt-1/PlGF ratio. This review summarizes the current evidence of the clinical application of the sFlt-1/PlGF ratio for the diagnosis and prognosis assessment of PE and points out the next challenges for these biomarkers, including their role as target for the development and monitoring of new therapies.</description><subject>Mini-Review</subject><issn>1015-3837</issn><issn>1421-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNo9kEtPwzAQhC0EouVx4I6Qj3AI9StOfKwKLUiVqICeI8exU0MexU6E-Pe4NPS0s9pvRtoB4Aqje4xjMUEIsSQRiB6BMWYER0Jwdhw0wnFEU5qMwJn3HwFLE8pPwYikCRap4GPQr7eF7DRsG9htNHywsmxabz2UTQFXrh221oRFa1XJeuuthN-22_wZprbYHXfSz6suwhO4qhZz-Co720LbwDfblJXuQn4IKBvZKKv9BTgxsvL6cpjnYD1_fJ89RcuXxfNsuowUZbiLlKKCkcJIahTSmEplFDXEmEKnKud5jCinUpKCppjkgonwsDEx45wrIQ2h5-B2n7t17VevfZfV1itdVbLRbe8zLAiiAieMBfRujyrXeu-0ybbO1tL9ZBhlu5azQ8uBvRli-7zWxYH8rzUA13vgU7pSuwMw-H8BvXCAMg</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Herraiz, Ignacio</creator><creator>Llurba, Elisa</creator><creator>Verlohren, Stefan</creator><creator>Galindo, Alberto</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4048-6407</orcidid><orcidid>https://orcid.org/0000-0003-3507-8636</orcidid></search><sort><creationdate>20180101</creationdate><title>Update on the Diagnosis and Prognosis of Preeclampsia with the Aid of the sFlt-1/ PlGF Ratio in Singleton Pregnancies</title><author>Herraiz, Ignacio ; Llurba, Elisa ; Verlohren, Stefan ; Galindo, Alberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c341t-cc3942dfa3fc0e13acfc3f2ffde8cb6b50363aa2d3812b949101ff54666c9af23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Mini-Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Herraiz, Ignacio</creatorcontrib><creatorcontrib>Llurba, Elisa</creatorcontrib><creatorcontrib>Verlohren, Stefan</creatorcontrib><creatorcontrib>Galindo, Alberto</creatorcontrib><creatorcontrib>Spanish Group for the Study of Angiogenic Markers in Preeclampsia</creatorcontrib><creatorcontrib>on behalf of the Spanish Group for the Study of Angiogenic Markers in Preeclampsia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Fetal diagnosis and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Herraiz, Ignacio</au><au>Llurba, Elisa</au><au>Verlohren, Stefan</au><au>Galindo, Alberto</au><aucorp>Spanish Group for the Study of Angiogenic Markers in Preeclampsia</aucorp><aucorp>on behalf of the Spanish Group for the Study of Angiogenic Markers in Preeclampsia</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Update on the Diagnosis and Prognosis of Preeclampsia with the Aid of the sFlt-1/ PlGF Ratio in Singleton Pregnancies</atitle><jtitle>Fetal diagnosis and therapy</jtitle><addtitle>Fetal Diagn Ther</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>43</volume><issue>2</issue><spage>81</spage><epage>89</epage><pages>81-89</pages><issn>1015-3837</issn><eissn>1421-9964</eissn><abstract>Preeclampsia (PE) is involved in a group of obstetrical conditions closely related by the presence of placental dysfunction (PD), which also includes intrauterine growth restriction and placental abruption. The timely and accurate recognition and management of PE are often challenging because diagnostic criteria are still based on nonspecific signs and symptoms and because common severity criteria correlate poorly with adverse maternal and fetal outcomes. The discovery of the role of angiogenesis-related factors - soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) - in the underlying pathophysiology of PD has marked an important step for improving its early diagnosis and prognosis assessment before gestational week 34. Nowadays, an sFlt-1/PlGF ratio cutoff level of ≤38 is widely accepted for ruling out PE in patients with suspicion of the disease, and its use is cost-effective. However, the evidence is more limited regarding the management and prognosis of women with an abnormally high sFlt-1/PlGF ratio. This review summarizes the current evidence of the clinical application of the sFlt-1/PlGF ratio for the diagnosis and prognosis assessment of PE and points out the next challenges for these biomarkers, including their role as target for the development and monitoring of new therapies.</abstract><cop>Basel, Switzerland</cop><pmid>28719896</pmid><doi>10.1159/000477903</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-4048-6407</orcidid><orcidid>https://orcid.org/0000-0003-3507-8636</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1015-3837
ispartof Fetal diagnosis and therapy, 2018-01, Vol.43 (2), p.81-89
issn 1015-3837
1421-9964
language eng
recordid cdi_karger_primary_477903
source Karger Journal Archive Collection; Karger Journals Complete; Alma/SFX Local Collection
subjects Mini-Review
title Update on the Diagnosis and Prognosis of Preeclampsia with the Aid of the sFlt-1/ PlGF Ratio in Singleton Pregnancies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A09%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Update%20on%20the%20Diagnosis%20and%20Prognosis%20of%20Preeclampsia%20with%20the%20Aid%20of%20the%20sFlt-1/%20PlGF%20Ratio%20in%20Singleton%20Pregnancies&rft.jtitle=Fetal%20diagnosis%20and%20therapy&rft.au=Herraiz,%20Ignacio&rft.aucorp=Spanish%20Group%20for%20the%20Study%20of%20Angiogenic%20Markers%20in%20Preeclampsia&rft.date=2018-01-01&rft.volume=43&rft.issue=2&rft.spage=81&rft.epage=89&rft.pages=81-89&rft.issn=1015-3837&rft.eissn=1421-9964&rft_id=info:doi/10.1159/000477903&rft_dat=%3Cproquest_karge%3E1920391744%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1920391744&rft_id=info:pmid/28719896&rfr_iscdi=true